http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8400382-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
filingDate 1983-07-08^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce839d95f37c62f1dab111c998b5202a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5424f6f449b3917a96dfbbadeb285885
publicationDate 1984-02-02^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-8400382-A1
titleOfInvention Improved protocol for the treatment of graft versus host disease
abstract A monoclonal antibody known as TA-1 directed against human T-cells and which is covalently linked to the toxin ricin and used to treat human donor bone marrow before the marrow is infused into a human recipient. Additionally, monoclonal antibodies known as TA-1, T101, and UCHT1 covalently linked to separate ricin toxins, are combined in a mixture and used in an improved protocol in the treatment of human donor bone marrow prior to the infusion of the marrow into a human recipient.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0193161-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8987426-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7125553-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7696338-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8601533-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5169939-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8217158-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2177096-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8911867-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6632928-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-762197-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0193161-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7288254-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9632137-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7517527-B2
priorityDate 1982-07-19^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4368149-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4363758-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4340535-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0063988-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0080401-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0074279-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4359457-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4397843-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4356117-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9836480
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226582022
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409359
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4362

Showing number of triples: 1 to 45 of 45.